SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from Adicet Bio, Inc. (ACET) (CIK 0001720580) (ACET) — May 5, 2022

Adicet Bio, Inc. (ACET) (CIK 0001720580)
Date: May 5, 2022 · CIK: 0001720580 · Accession: 0000950170-22-007926

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-263587

Date
May 5, 2022
Author
/s/ Chen Schor
Form
CORRESP
Company
Adicet Bio, Inc. (ACET) (CIK 0001720580)

Letter

Adicet Bio, Inc.

200 Clarendon Street, Floor 6

Boston, Massachusetts 02116

May 5, 2022

Via EDGAR Transmission

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 15, 2022 (File No. 333-263587), as amended

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Adicet Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to May 9, 2022, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

Once the Registration Statement is effective, please orally confirm the event with Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. If you have any questions regarding this request, please contact Gabriela Morales-Rivera.

Sincerely,
Adicet Bio, Inc.

Show Raw Text
CORRESP
1
filename1.htm

  CORRESP

  Adicet Bio, Inc.

  200 Clarendon Street, Floor 6

  Boston, Massachusetts 02116

  May 5, 2022

  Via EDGAR Transmission

  United States Securities and Exchange Commission

  Division of Corporation Finance

  100 F Street, N.E.

  Washington, D.C. 20549

  Re:     Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 15, 2022 (File No. 333-263587), as amended

  Ladies and Gentlemen:

   Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Adicet Bio, Inc. (the “Company”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “Registration Statement”) be accelerated to May 9, 2022, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time.  In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

  Once the Registration Statement is effective, please orally confirm the event with Goodwin Procter LLP by calling Gabriela Morales-Rivera at (617) 570-1329. If you have any questions regarding this request, please contact Gabriela Morales-Rivera.

  Sincerely,

  Adicet Bio, Inc.

   /s/ Chen Schor

  Chen Schor

  President and Chief Executive Officer

  cc:        Nick Harvey, Chief Financial Officer, Adicet Bio, Inc.

      Danielle Lauzon, Esq., Goodwin Procter LLP

               Gabriela Morales-Rivera, Esq., Goodwin Procter LLP